Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JuntuCell
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
JuntuCell is a China-based biotechnology company specializing in the development of next-generation cell therapies for oncology. The company focuses on overcoming the limitations of current CAR-T treatments by developing universal, off-the-shelf cell products and therapies targeting solid tumors. Their research encompasses CAR-T, TCR-T, and NK cell-based modalities, utilizing advanced gene editing and cell engineering technologies. JuntuCell aims to improve the accessibility and efficacy of immunotherapy for patients with hematological malignancies and difficult-to-treat solid cancers.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyCAR-T cell therapyNK cell therapyT cell receptor engineered T cell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on JuntuCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JuntuCell.